Vitruvias Therapeutics announced on August 21, 2026 that it was recalling one lot of its Thyroid Tablets, USP 30 mg after testing confirmed the potential for superpotency. FDA published the company announcement on August 24 as a public-service posting, not an FDA endorsement.
The notice identifies lot 504950 with a listed expiration date of September 30, 2026. It says the lot was distributed nationwide through company direct accounts in 2025. That printed expiry had passed by this October 7 source check.
The company notice says patients taking this lot should contact a health-care provider before stopping or changing treatment. It does not describe a recall of all thyroid medicines or all lots.